1)
SD2008-289
- G alpha i - GIV Interface as a Novel Therapeutic Target. (Ghosh, Garcia-Marcos, M., and Farquhar,
M.G.).
2)
SD2008-289
– Tumoral GIV as a novel biomarker for prognostication in carcinomas. (Ghosh, P., Garcia-Marcos, M., and
Farquhar, M.G.). Licensed antibody production (for research purpose) with Millipore Inc. Licensing underway (for diagnostics purposes) with Roche Diagnostics.
3)
SD2008-289
- GIV as a serum biomarker for metastatic progression of carcinomas. (Ghosh and Garcia-Marcos).
4)
SD2010-066- A Marker and Therapeutic Target for the PI3K Pathway. Licensing
completed with
Roche
Diagnostics (for diagnostics applications) and with Millipore
Inc. (for research applications).
5)
SD2013-019:
A Novel Diagnostic and Therapeutic Target within the
Wnt Pathway- (Molecular Basis for Aberrant Signal Amplification in Leukemia,
Lymphomas, Solid tumors (breast/Colon) during early oncogenesis and during
developmental disorders of the brain). Licensed
with Millipore
Inc. (for research applications).
6)
SD2013-243:
Title of Invention A Blood Test to Prognosticate
Progression-Free and Overall Survival in Cancer Patients. Licensing underway with a San Diego-based
Biotech Company.
7)
SD2014-148:
A Method to Predict and Treat Liver Fibrosis and
other Fibrogenic Disorders. Licensing underway with Ventana Inc (a branch of Roche Diagnostics).
8)
SD2014-186: G-alpha, interacting vesicle associated protein (giv)
as a prognositic in stage ii colorectal cancer. Joint IP with Ventana
Inc (a branch of Roche
Diagnostics).
9)
SD-2014-259 -
Detection and Treatment of GIV-associated Cancer.
10)
SD2014-283-1
- Method to assemble, visualize and measure RTK-G protein complexes in cells.